Loading…
Biomea Fusion, Inc. is projected to decline to $1.30 by 2027, a -1% move from its current price of $1.32. BMEA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.27 | $1.32 | $1.37 | -0.02% |
| Jul 13 | $1.25 | $1.32 | $1.39 | -0.05% |
| Jul 14 | $1.24 | $1.32 | $1.41 | -0.07% |
| Jul 15 | $1.22 | $1.32 | $1.42 | -0.10% |
| Jul 16 | $1.21 | $1.32 | $1.43 | -0.12% |
| Jul 17 | $1.20 | $1.32 | $1.44 | -0.15% |
| Jul 18 | $1.19 | $1.32 | $1.45 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.19 | $1.32 | $1.45 | -0.17% |
| Week 2 | $1.15 | $1.32 | $1.51 | -0.35% |
| Week 3 | $1.11 | $1.31 | $1.56 | -0.52% |
| Week 4 | $1.08 | $1.31 | $1.59 | -0.69% |
| Week 5 | $1.05 | $1.31 | $1.63 | -0.86% |
| Week 6 | $1.03 | $1.31 | $1.66 | -1.03% |
| Week 7 | $1.01 | $1.30 | $1.69 | -1.20% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biomea Fusion, Inc. is a clinical-stage healthcare company focused on the discovery and development of oral medicines to treat diabetes and obesity. Its lead clinical programs include COVALENT-111 and COVALENT-112, with icovamenib having completed Phase II trials for the treatment of Type 1 and Type 2 diabetes; COVALENT-211 is in Phase II for insulin-deficient type 2 diabetes, and COVALENT-212 is in Phase II for type 2 diabetes.
The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trials for obesity.
Biomea Fusion was incorporated in 2017 and is headquartered in San Carlos, California.
Biomea Fusion, Inc. trades with the symbol BMEA and has a current price of $1.39 with a market cap of $100.5M, ranking 3982 by market size.
The near-term technical picture remains neutral, while the longer-term outlook shows a path of growth in the forecast horizon. The 30-day technical setup places the stock in a tight range with mixed signals before a potential longer-term uptrend materializes.
A major floor 26.3% below — a decisive break under it would weaken the trend.
The nearest floor, 14.0% below — buyers have tended to step in here.
The nearest ceiling, 11.4% above — a clean break opens room to run.
A major ceiling 67.4% above — clearing it would confirm fresh momentum.
Key BMEA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BMEA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.34 | Sell | $1.33 | Sell |
| MA 10 | $1.37 | Sell | $1.33 | Sell |
| MA 20 | $1.29 | Buy | $1.32 | Sell |
| MA 50 | $1.35 | Sell | $1.36 | Sell |
| MA 100 | $1.43 | Sell | $1.40 | Sell |
| MA 200 | $1.42 | Sell | $1.65 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.59 | Neutral |
| Stoch RSI (14) | 27.84 | Neutral |
| CCI (20) | 28.81 | Neutral |
| Williams %R (14) | -62.50 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 7.32 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 37.50 | Neutral |
| TRIX (15) | -0.07 | Sell |
| Awesome (5,34) | 0.04 | Buy |
| Ultimate (7,14,28) | 39.71 | Neutral |
| Momentum (10) | 0.09 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 1.30 | Buy |
| ADX (14) | 12.74 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is NEUTRAL. RSI14 stands at 60, with the 50-day simple moving average around $1.43 and the 200-day simple moving average around $1.45, indicating a collection of price averages nearby.
Support is at $1.13 and resistance at $1.42, defining a near-term trading range close to the current price. The 30-day range spans from $1.09 to $1.78, highlighting modest volatility within the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.09 | $1.32 | $1.68 | 0% | Neutral | |
| $1.00 | $1.30 | $1.81 | -1% | Neutral | |
| $1.07 | $1.44 | $2.10 | +9% | Neutral | |
| $0.987 | $1.38 | $2.08 | +4% | Neutral | |
| $1.21 | $1.74 | $2.71 | +32% | Bullish | |
| $1.41 | $2.08 | $3.34 | +58% | Bullish | |
| $1.35 | $2.05 | $3.36 | +55% | Bullish | |
| $1.32 | $2.04 | $3.43 | +55% | Bullish | |
| $1.23 | $1.96 | $3.35 | +49% | Bullish | |
| $1.32 | $2.14 | $3.72 | +62% | Bullish | |
| $1.65 | $2.98 | $5.59 | +126% | Bullish | |
| $2.77 | $6.00 | $12.56 | +354% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.09 | $1.32 | $1.63 | +0.00% |
| August 2026 | $1.14 | $1.35 | $1.67 | +2.55% |
| September 2026 | $1.07 | $1.29 | $1.61 | -4.66% |
| October 2026 | $1.06 | $1.28 | $1.62 | -0.68% |
| November 2026 | $1.08 | $1.32 | $1.69 | +3.02% |
| December 2026 | $1.06 | $1.30 | $1.68 | -1.32% |
Click any year to see its month-by-month BMEA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BMEA is projected to trade between $1.09 and $1.68, averaging $1.32 — a potential gain of 0% from today's $1.32. Price action looks broadly range-bound.
Biomea Fusion, Inc.'s 2027 outlook centres on $1.30, within a $1.00 to $1.81 range. That is -1% versus the projected 2026 average. That marks a -1% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, BMEA could reach as high as $2.10, with a base case around $1.44 and support toward $1.07 — roughly +9% from $1.32. Price action looks broadly range-bound.
Expect BMEA to range from $0.987 to $2.08 through 2029. The $1.38 average target implies a +4% move from current prices. That is -4% versus the projected 2028 average. A consolidation phase looks the most probable path here.
The BMEA price prediction for 2030 points to an average of $1.74 (low $1.21, high $2.71) — a potential gain of +32% on today's $1.32. Momentum favours further upside here.
In 2031, BMEA is projected to trade between $1.41 and $3.34, averaging $2.08 — a potential gain of +58% from today's $1.32. That is up +20% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Biomea Fusion, Inc.'s 2032 outlook centres on $2.05, within a $1.35 to $3.36 range. That is -2% versus the projected 2031 average. That marks a +55% change versus current levels. Momentum favours further upside here.
By 2033, BMEA could reach as high as $3.43, with a base case around $2.04 and support toward $1.32 — roughly +55% from $1.32. Buyers look set to stay in control over this stretch.
Expect BMEA to range from $1.23 to $3.35 through 2034. The $1.96 average target implies a +49% move from current prices. That is -4% versus the projected 2033 average. Momentum favours further upside here.
The BMEA price prediction for 2035 points to an average of $2.14 (low $1.32, high $3.72) — a potential gain of +62% on today's $1.32. Buyers look set to stay in control over this stretch.
In 2040, BMEA is projected to trade between $1.65 and $5.59, averaging $2.98 — a potential gain of +126% from today's $1.32. That is up +39% on the projected 2035 average. Momentum favours further upside here.
Biomea Fusion, Inc.'s 2050 outlook centres on $6.00, within a $2.77 to $12.56 range. That is up +101% on the projected 2040 average. That marks a +354% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in BMEA today (≈ 757.575758 BMEA) could be worth
$4,543.92
+$3,543.92 (+354%) by 2050 · US Dollar
Based on the average projected BMEA price of $6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BMEAwould be worth at today's price.
$1,000 invested in BMEA on Jul 10, 2025 (≈ 518.134729 BMEA) would be worth
$683.94
-$316.06 (-31.6%) today · 0.68× · US Dollar
Based on a BMEA entry price of $1.93 vs. today's $1.32.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.41 | $936.17 | -6.4% |
| 1 month ago | $1.15 | $1,147.83 | +14.8% |
| 3 months ago | $1.87 | $705.88 | -29.4% |
| 6 months ago | $1.46 | $904.11 | -9.6% |
| 1 year ago | $1.93 | $683.94 | -31.6% |
| All time (5.0y) ago | $15.99 | $82.55 | -91.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BMEA forecast.
Our base-case forecast reaches $2.60 around 2040.
Implied market cap at $2.60: $187.98M
The multi-year forecast shows a gradual price uplift with rising sentiment starting in 2030. For 2026 the average price is $1.39 with a neutral sentiment; 2027’s average is $1.41; 2028’s average is $1.57; 2029’s average is $1.50. In 2030 the average is $1.97 with bullish sentiment and a 41.9 ROI.
The trajectory continues higher through 2031 (avg $2.36, ROI 69.6), 2032 (avg $2.25, ROI 61.9), 2033 (avg $2.31, ROI 66), 2034 (avg $2.24, ROI 61.3), and 2035 (avg $2.44, ROI 75.3).
By 2040 the forecasted average price is $3.45 with a 148 ROI and bullish sentiment, and by 2050 the average climbs to $6.99 with a 403.2 ROI, maintaining a bullish outlook.
These figures illustrate upside potential over the long term, but they are estimates and not guarantees. Investors should recognize the inherent uncertainty and risk associated with small-cap healthcare equities and price forecasts.
Tap a question to reveal the answer.
2030 avg $1.97 with min $1.37 and max $3.09; ROI 41.9; sentiment BULLISH.
Near-term outlook (2026–2029) is NEUTRAL, with average prices around $1.39–$1.50. From 2030 onward, the forecast turns BULLISH with higher upside, including a 2030 avg of $1.97 and a 2030 max of $3.09; long-term upside is projected to 2040 and 2050 with notable ROIs, though these are estimates, not guarantees.
Yes. The forecast shows a 2030 max of $3.09, a 2031 max of $3.79, a 2032 max of $3.71, a 2033 max of $3.88, a 2034 max of $3.85, and a 2035 max of $4.26.
Current price is $1.39 and market cap is $100.5M.
Sentiment is NEUTRAL. RSI 14 = 60. SMA50 = $1.43. SMA200 = $1.45. Support = $1.13. Resistance = $1.42. Thirty-day range: $1.09 to $1.78.
Biomea Fusion, Inc. Community Discussion
0Share your Biomea Fusion, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.